X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (33) 33
male (24) 24
aged (23) 23
female (23) 23
middle aged (23) 23
adult (22) 22
index medicus (21) 21
oncology (18) 18
cancer (17) 17
life sciences (15) 15
aged, 80 and over (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
camptothecin - administration & dosage (9) 9
camptothecin - analogs & derivatives (9) 9
colorectal cancer (9) 9
fluorouracil (8) 8
fluorouracil - administration & dosage (8) 8
chemotherapy (7) 7
colorectal neoplasms - pathology (7) 7
genetics & heredity (7) 7
leucovorin (7) 7
leucovorin - administration & dosage (7) 7
survival (7) 7
adaptor proteins, signal transducing (6) 6
carcinoma (6) 6
colorectal neoplasms - drug therapy (6) 6
colorectal neoplasms, hereditary nonpolyposis - genetics (6) 6
hnpcc (6) 6
mutation (6) 6
mutl protein homolog 1 (6) 6
nonpolyposis colorectal-cancer (6) 6
organoplatinum compounds - administration & dosage (6) 6
oxaliplatin (6) 6
tumors (6) 6
adenocarcinoma - drug therapy (5) 5
adenocarcinoma - secondary (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
colorectal neoplasms - genetics (5) 5
disease-free survival (5) 5
genetic predisposition to disease (5) 5
irinotecan (5) 5
metastasis (5) 5
neoplasm metastasis (5) 5
nuclear proteins (5) 5
other (5) 5
prognosis (5) 5
research (5) 5
retrospective studies (5) 5
risk factors (5) 5
survival analysis (5) 5
5-fluorouracil (4) 4
[ sdv.can ] life sciences [q-bio]/cancer (4) 4
adenocarcinoma (4) 4
adenocarcinoma - mortality (4) 4
adenocarcinoma - pathology (4) 4
camptothecin - adverse effects (4) 4
care and treatment (4) 4
cetuximab (4) 4
deoxycytidine - analogs & derivatives (4) 4
digestive system diseases (4) 4
dna-binding proteins - genetics (4) 4
drug administration schedule (4) 4
genetics (4) 4
germ-line mutation (4) 4
mesh : adult (4) 4
mesh : humans (4) 4
mesh : middle aged (4) 4
metastatic colorectal cancer (4) 4
mlh1 (4) 4
neoplasms (4) 4
nuclear proteins - genetics (4) 4
pancreas (4) 4
pancreatic neoplasms - drug therapy (4) 4
pancreatic neoplasms - pathology (4) 4
pedigree (4) 4
prospective studies (4) 4
risk assessment (4) 4
[sdv]life sciences [q-bio] (3) 3
abridged index medicus (3) 3
adolescent (3) 3
age (3) 3
antimetabolites, antineoplastic - therapeutic use (3) 3
biomarker (3) 3
carrier proteins (3) 3
cetuximab given every 2 weeks (3) 3
clinical trials (3) 3
colon cancer (3) 3
colonic neoplasms - genetics (3) 3
colorectal carcinoma (3) 3
deoxycytidine - therapeutic use (3) 3
disease progression (3) 3
dna mismatch repair (3) 3
drug therapy (3) 3
families (3) 3
fluorouracil - adverse effects (3) 3
follow-up studies (3) 3
france (3) 3
further section (3) 3
gemcitabine (3) 3
gene (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Human Genetics, ISSN 1018-4813, 01/2016, Volume 24, Issue 1, pp. 99 - 105
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 1, pp. 23 - 29
Journal Article
JAMA, ISSN 0098-7484, 06/2011, Volume 305, Issue 22, pp. 2304 - 2310
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2011, Volume 364, Issue 19, pp. 1817 - 1825
In this study, a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more... 
PHASE-III TRIAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | CLINICAL-TRIALS | IRINOTECAN | OXALIPLATIN | 1ST-LINE THERAPY | COMBINATION | CARCINOMA | COOPERATIVE-ONCOLOGY-GROUP | Leucovorin - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Adult | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Camptothecin - analogs & derivatives | Severity of Illness Index | Pancreatic Neoplasms - pathology | Proportional Hazards Models | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Survival Analysis | Quality of Life | Aged | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Chemotherapy, Combination | Usage | Care and treatment | Gemcitabine | Pancreatic cancer | Leucovorin | Comparative analysis | Drug therapy | Fluorouracil | Clinical trials | Cytotoxicity | Pancreas | Patients | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 7, pp. 674 - 681
Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer... 
NON-INFERIORITY | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | THERAPY | ONCOLOGY | IRINOTECAN | OPEN-LABEL | OXALIPLATIN | FOLFIRI PLUS BEVACIZUMAB | FLUOROURACIL | Life Sciences | Cancer
Journal Article
Palliative and Supportive Care, ISSN 1478-9515, 06/2013, Volume 13, Issue 3, pp. 801 - 807
Since the description by Yaskin in 1931, it has been observed that pancreatic cancer and depression are two clinical entities that share a high affinity. This... 
Mood disorders | Depression assessment | Psycho-oncology | Pancreas | Cancer | Depressive Disorder, Major - psychology | Depressive Disorder, Major - etiology | Humans | Middle Aged | Adult | Pancreatic Neoplasms - psychology | Surveys and Questionnaires | Aged | Retrospective Studies | Prodromal Symptoms | Pancreatic Neoplasms - complications
Journal Article
Journal Article
Journal Article
Neuro-Oncology, ISSN 1522-8517, 06/2018, Volume 20, Issue suppl_2, pp. i125 - i125
Abstract Medulloblastoma may occur in a context of APC germline mutation and familial adenomatous polyposis. We aimed to describe clinical features of patients... 
Abstracts
Journal Article
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 50, pp. 82953 - 82960
Background: We sought to assess the benefit-risk balance of FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic adenocarcinoma. Methods: We... 
Statistics as topic | Benefit-risk assessment | Multi-criteria analysis | Randomized controlled trial | Pancreatic cancer | PLUS GEMCITABINE | SURVIVAL | HAZARD RATIO | benefit-risk assessment | GENERALIZED PAIRWISE COMPARISONS | RANDOMIZED CLINICAL-TRIALS | CANCER | randomized controlled trial | CELL BIOLOGY | pancreatic cancer | INVESTIGATORS | ENHANCE COMMUNICATION | multi-criteria analysis | OUTCOMES | statistics as topic | ERLOTINIB | Leucovorin - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Pancreatic Neoplasms - drug therapy | Deoxycytidine - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | Camptothecin - administration & dosage | Deoxycytidine - adverse effects | Pancreatic Neoplasms - mortality | Camptothecin - analogs & derivatives | Risk Assessment | Pancreatic Neoplasms - pathology | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Index Medicus | Life Sciences
Journal Article
Medicine, ISSN 0025-7974, 10/2015, Volume 94, Issue 42, p. e1864
Neuroendocrine carcinomas (NEC) of the anus or the rectum are a rare disease, accounting for less than 1% of all digestive malignancies. Most are metastatic at... 
Life Sciences
Journal Article
The oncologist, ISSN 1083-7159, 06/2019, p. theoncologist.2018-0786
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy with a median overall survival (OS) of between 8 and 11 months. However, a... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. e15251 - e15251
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2007, Volume 60, Issue 3, pp. 383 - 389
Journal Article